| Date | Time | Source | |
| 03/16/2010 | 4:15PM | PRNUS | Watson to Present at Barclay's 2010 Global Healthcare Conference
Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's president and chief executive officer, will provide an overview and update of the Company's business at the Barclay's 2010 Global Healthcare Conference on Tuesday, March 23, 2010 at 11:15 am... More...>> |
| 03/15/2010 | 4:02PM | PRNUS | Watson Receives FDA Approval for Generic Cardizem(R) LA
Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc. – Florida, has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride Extended-Release tablets, the generic equivalent to Biovail... More...>> |
| 03/11/2010 | 4:15PM | PRNUS | FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of
Watson Pharmaceuticals, Inc. , today announced the U.S. Food and Drug Administration (FDA) approval of TRELSTAR ® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR ®, a proven, simple and effective palliative treatment of advanced prostate cancer. With... More...>> |
| 03/08/2010 | 4:38PM | PRNUS | Watson Confirms Filing of Generic Opana(R) ER Application
Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has been sued by Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for Oxymorphone Hydrochloride... More...>> |
| 03/04/2010 | 8:18AM | DJN | Watson To Buy US Rights To Columbia Labs' Fertility Gels
DOW JONES NEWSWIRES Watson Pharmaceuticals Inc. (WPI) has agreed to buy exclusive U.S. rights to Columbia Laboratories Inc.'s (CBRX) Crinone and Prochieve products, used to help fertility and carry out pregnancies. Under the agreement, Watson will pay Columbia $47 million upfront in exchange for the rights and 11.2 million... More...>> |
| 03/04/2010 | 7:05AM | PRNUS | Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories' CRINONE(R) Progesterone Gel Product Line
Watson Pharmaceuticals, Inc. today announced an agreement to expand their Women's Health brand product portfolio with the acquisition of the exclusive U.S. rights to Columbia Laboratories, Inc.'s bioadhesive progesterone gel products currently marketed under the trade names CRINONE ® and PROCHIEVE ® for... More...>> |
| 03/04/2010 | 7:00AM | BW | Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
Columbia Laboratories, Inc. (Nasdaq: CBRX) has entered into a definitive agreement to sell substantially all of its progesterone related assets and 11.2 million shares of common stock to Watson Pharmaceuticals, Inc. (NYSE: WPI) for a $47 million upfront payment plus royalties of 10 to 20 percent of annual net sales of... More...>> |
| 03/03/2010 | 4:15PM | MWUS | Watson to Present at Cowen and Company 30th Annual Healthcare Conference
Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's president and chief executive officer, will provide an overview and update of the Company's business at the Cowen and Company 30th Annual Healthcare Conference on Tuesday, March 9, 2010 at 11:05... More...>> |
| 03/01/2010 | 6:33PM | DJN | UPDATE: Watson Pharma To Sell ScinoPharm Taiwan Stake For $94 Million
(Adds name of buyer) DOW JONES NEWSWIRES Watson Pharmaceuticals Inc. (WPI) has agreed to sell its 31% stake in contract manufacturer ScinoPharm Taiwan Ltd. for about $94 million, saying the relationship had grown less strategic to Watson's growth. Uni-President Enterprises Corp. (1216.TW), Taiwan's largest food producer... More...>> |
| 03/01/2010 | 6:08PM | DJN | Watson Pharma To Sell 31% Stake In ScinoPharm Taiwan For $94 Million
DOW JONES NEWSWIRES Watson Pharmaceuticals Inc. (WPI) has agreed to divest its 31% stake in contract manufacturer ScinoPharm Taiwan Ltd. for about $94 million, saying the relationship had grown less strategic to Watson's growth. The deal, expected to close in the first half of this year, requires approval from various... More...>> |
| 03/01/2010 | 5:08PM | PRNUS | Watson Signs Agreement to Divest Equity Interest in ScinoPharm
Watson Pharmaceuticals, Inc. today announced that it signed an agreement on February 26, 2010 to divest its equity ownership position of approximately 31% of ScinoPharm Taiwan Ltd. The transaction is subject to the parties obtaining approvals from various government agencies in Taiwan, as well as other customary closing... More...>> |
| 03/01/2010 | 8:00AM | PRNUS | Watson Licenses Population Council's Novel Contraceptive Ring
Watson Pharmaceuticals, Inc. today announced an exclusive licensing agreement to commercialize the Population Council's investigational contraceptive vaginal ring in the United States, Canada, and Mexico. The ring, which contains two hormonal products - ethinyl estradiol and Nestorone ®, a novel, synthetic progestin... More...>> |
| 02/26/2010 | 8:30AM | PRNUS | Watson to Present at CLSA/Asia USA Investor's Forum
Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's president and chief executive officer, will provide an overview of the Company's business at the CLSA/Asia Investor's Forum on Tuesday, March 2, 2010 at 4:30 pm Eastern Standard Time at the Westin St. Francis... More...>> |
| 02/23/2010 | 5:38PM | DJN | 2nd UPDATE: US Judge Ends FTC Challenge To AndroGel Pact
A U.S. trial judge has dismissed a Federal Trade Commission antitrust lawsuit alleging Abbott Laboratories (ABT) unit Solvay Pharmaceuticals conspired with generic drug makers to postpone generic competition for its leading testosterone-replacement drug AndroGel. The ruling is a setback in the FTC's ongoing campaign against... More...>> |
| 02/23/2010 | 4:17PM | DJN | UPDATE:US Judge Dismisses FTC Challenge To AndroGel Settlement
A U.S. trial judge has dismissed a Federal Trade Commission antitrust lawsuit alleging Abbott Laboratories (ABT) unit Solvay Pharmaceuticals conspired with generic drug makers to postpone generic competition for its leading testosterone-replacement drug AndroGel. The ruling is a setback in the FTC's ongoing campaign against... More...>> |
| 02/23/2010 | 2:18PM | DJN | CORRECT:US Judge Dismisses FTC Challenge To AndroGel Settlement
A federal trial judge has dismissed a U.S. Federal Trade Commission antitrust lawsuit alleging that Abbott Laboratories (ABT) unit Solvay Pharmaceuticals conspired with generic drug makers to postpone generic competition for its leading testosterone-replacement drug AndroGel. The FTC had alleged last year that Solvay... More...>> |
| 02/23/2010 | 1:33PM | DJN | US Judge Dismisses FTC Challenge To AndroGel Settlement
A federal trial judge has dismissed a U.S. Federal Trade Commission antitrust lawsuit alleging that Solvay SA (SOLB.BT) conspired with generic drug makers to postpone generic competition for its leading testosterone-replacement drug AndroGel. The FTC had alleged last year that Solvay, faced with the prospect of plummeting... More...>> |
| 02/23/2010 | 7:30AM | PRNUS | Watson Reports Net Revenue of $786 Million for the Fourth Quarter 2009
Watson Pharmaceuticals, Inc. (NYSE:WPI) today reported net revenue for the fourth quarter ended December 31, 2009 climbed 22 percent to $785.7 million, compared to $645.2 million in the fourth quarter 2008. Watson's results include Arrow Group results since the acquisition on December 2, 2009. On an adjusted cash basis... More...>> |
| 02/22/2010 | 8:00AM | PRNUS | Watson Files FDA Application for Generic Aplenzin(TM) ER
Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.- Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 174 mg and 348 mg strength bupropion... More...>> |
| 02/02/2010 | 8:30AM | PRNUS | Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that the Company intends to release its fourth quarter 2010 financial results on Tuesday, February 23, 2010 prior to the open of the U.S. financial markets. The Company will also host a conference call and webcast at 8:30... More...>> |